Pro-Dex (NASDAQ:PDEX) Lowered to Hold Rating by StockNews.com

Pro-Dex (NASDAQ:PDEX - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday.

Pro-Dex Stock Down 2.6 %

NASDAQ:PDEX traded down $1.25 during midday trading on Wednesday, reaching $46.53. 47,281 shares of the stock traded hands, compared to its average volume of 33,282. The business has a 50-day moving average of $39.93 and a two-hundred day moving average of $37.82. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. Pro-Dex has a 12-month low of $16.83 and a 12-month high of $59.60. The stock has a market capitalization of $151.73 million, a PE ratio of 23.15 and a beta of 0.68.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, equities analysts forecast that Pro-Dex will post 2 earnings per share for the current fiscal year.

Insider Activity at Pro-Dex

In other Pro-Dex news, Director Raymond E. Cabillot sold 1,200 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $47.76, for a total value of $57,312.00. Following the sale, the director now directly owns 359,646 shares of the company's stock, valued at approximately $17,176,692.96. This trade represents a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 35,444 shares of company stock valued at $1,584,642 in the last ninety days. Company insiders own 47.50% of the company's stock.

Hedge Funds Weigh In On Pro-Dex

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in shares of Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Pro-Dex during the fourth quarter valued at approximately $202,000. Trexquant Investment LP purchased a new position in shares of Pro-Dex in the fourth quarter valued at approximately $252,000. Integrated Quantitative Investments LLC acquired a new stake in shares of Pro-Dex in the fourth quarter worth approximately $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Pro-Dex during the fourth quarter worth approximately $255,000. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads